FluoGuide A/S (SE:FLUO)
:FLUO
Want to see SE:FLUO full AI Analyst Report?
Top Page
FluoGuide A/S
(FLUO)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr45.00
▲(25.00% Upside)
Action:Reiterated
Date:05/28/26
The score is primarily held down by weak financial performance—minimal revenue, large operating losses, and significant ongoing cash burn—despite positive equity and manageable leverage. Technical signals are mixed with subdued momentum, and valuation is difficult to support given negative earnings and no dividend yield provided.
Positive Factors
Balance sheet buffer
The balance sheet still shows positive shareholders' equity (43.1m TTM) and a moderate debt-to-equity profile (~0.52x), providing tangible financial flexibility. This cushion supports continued R&D and trial activity over months, reducing immediate insolvency risk while the company pursues commercialization.
Negative Factors
Material cash burn
The company is generating materially negative operating and free cash flow (TTM OCF ~-42.1m; FCF ~-37.5m). Persistent large cash burn erodes runway and forces reliance on external capital, which can dilute existing shareholders and distract management from long-term execution if financing becomes frequent or costly.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet buffer
The balance sheet still shows positive shareholders' equity (43.1m TTM) and a moderate debt-to-equity profile (~0.52x), providing tangible financial flexibility. This cushion supports continued R&D and trial activity over months, reducing immediate insolvency risk while the company pursues commercialization.
Read all positive factors
FluoGuide A/S (FLUO) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr734.08M
Dividend YieldN/A
Average Volume (3M)8.21K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue GrowthN/A
EPS Growth-20.67%
CountrySE
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-2.89
Shares Outstanding16,349,314
10 Day Avg. Volume11,579
30 Day Avg. Volume8,206
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)6.10
Price to Sales (P/S)0.00
P/FCF Ratio-8.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.98
Revenue Forecast (FY)N/A
FluoGuide A/S Business Overview & Revenue Model
Company Description
FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grad...
How the Company Makes Money
Public, company-specific details on FluoGuide A/S’s current revenue model and revenue breakdown (e.g., product sales vs. licensing vs. milestone payments), as well as specific named commercial partnerships and their financial terms, are not availa...
FluoGuide A/S Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 57.00K | 0.00 | 385.00K | 423.00K | 6.51M | 9.61M |
| Gross Profit | -280.78K | -571.17K | 385.00K | 423.00K | 6.51M | 9.61M |
| EBITDA | -42.77M | -40.42M | -32.81M | -43.90M | -32.21M | -28.65M |
| Net Income | -42.55M | -40.39M | -28.96M | -38.38M | -27.34M | -23.77M |
Balance Sheet | ||||||
| Total Assets | 76.26M | 88.34M | 28.38M | 29.61M | 35.62M | 53.31M |
| Cash, Cash Equivalents and Short-Term Investments | 63.24M | 78.84M | 18.61M | 21.67M | 26.01M | 46.76M |
| Total Debt | 27.93M | 28.30M | 624.00K | 10.83M | 205.00K | 57.00K |
| Total Liabilities | 33.13M | 33.78M | 5.31M | 16.89M | 3.65M | 14.61M |
| Stockholders Equity | 43.13M | 54.56M | 23.07M | 12.72M | 31.97M | 38.70M |
Cash Flow | ||||||
| Free Cash Flow | -42.53M | -37.83M | -30.00M | -31.81M | -37.71M | -15.06M |
| Operating Cash Flow | -42.06M | -37.83M | -29.15M | -31.81M | -37.65M | -15.06M |
| Investing Cash Flow | -30.34M | -30.61M | -987.00K | -37.00K | -117.00K | 0.00 |
| Financing Cash Flow | 85.14M | 99.33M | 27.08M | 27.50M | 17.02M | 51.18M |
FluoGuide A/S Technical Analysis
Positive
36.00
Price Trends
42.58
Positive
38.71
Positive
38.93
Positive
Market Momentum
0.84
Positive
54.53
Neutral
41.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLUO, the sentiment is Positive. The current price of 36 is below the 20-day moving average (MA) of 44.12, below the 50-day MA of 42.58, and below the 200-day MA of 38.93, indicating a bullish trend. The MACD of 0.84 indicates Positive momentum. The RSI at 54.53 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:FLUO.
FluoGuide A/S Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr643.53M | -40.98 | -48.65% | ― | 79.13% | 55.77% | |
48 Neutral | kr31.30M | -0.39 | -186.13% | ― | ― | 57.42% | |
44 Neutral | kr734.08M | -11.75 | ― | ― | ― | -20.67% | |
44 Neutral | kr401.27M | -5.38 | -79.60% | ― | ― | 51.40% | |
44 Neutral | kr176.04M | -1.52 | -199.86% | ― | -6.59% | 27.05% | |
41 Neutral | kr323.07M | -1.92 | -108.15% | ― | 106.74% | 89.96% |
* Healthcare Sector Average
SE:FLUO
FluoGuide A/S
44.90
5.10
12.81%
SE:QLINEA
Q-linea AB
17.35
-30.18
-63.49%
SE:ACE
Ascelia Pharma AB
3.01
-1.28
-29.87%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.24
-4.86
-79.63%
SE:GUARD
Guard Therapeutics International AB
1.55
-16.20
-91.26%
SE:NANEXA
Nanexa AB
3.91
1.66
73.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.